Annuncio • Jun 06
Genetic Technologies Limited (ASX:GTG) signed a letter of intent to acquire Walker Capital Private Wealth Pty Ltd from Michael Walker for AUD 0.84 million. Genetic Technologies Limited (ASX:GTG) signed a letter of intent to acquire Walker Capital Private Wealth Pty Ltd from Michael Walker for AUD 0.84 million on June 5, 2025. The consideration consists of common equity of Genetic Technologies Limited having a value of AUD 0.84 million to be issued for common equity of Walker Capital Private Wealth Pty Ltd. As part of consideration, AUD 0.84 million is paid towards common equity of Walker Capital Private Wealth Pty Ltd.
The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders and consummation of due diligence investigation, reinstatement to the Official List of the ASX and completion of associated capital raising. Annuncio • May 14
Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of AUD 0.268668 million. Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of AUD 0.268668 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 26,493,450
Price\Range: AUD 0.00004
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,163,511,764
Price\Range: AUD 0.00023
Transaction Features: Subsequent Direct Listing Annuncio • Apr 16
Genetic Technologies Limited, Annual General Meeting, May 14, 2025 Genetic Technologies Limited, Annual General Meeting, May 14, 2025. Location: level 2, 350 kent street, sydney nsw 200, sydney Australia Annuncio • Jan 15
An undisclosed buyer agreed to acquire Direct-to-Consumer business and assets of Genetic Technologies Limited (ASX:GTG). An undisclosed buyer entered into an Asset Sale Agreement to acquire Direct-to-Consumer business and assets of Genetic Technologies Limited (ASX:GTG) on January 15, 2025.
The expected completion of the transaction is January 20, 2025. Annuncio • Dec 18
Genetic Technologies Limited(NasdaqCM:GENE) dropped from NASDAQ Composite Index Genetic Technologies Limited has been dropped from the NASDAQ Composite Index Annuncio • Nov 27
Genetic Technologies Limited has withdrawn its Follow-on Equity Offering in the amount of AUD 0.324648 million. Genetic Technologies Limited has withdrawn its Follow-on Equity Offering in the amount of AUD 0.324648 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 8,116,205
Price\Range: AUD 0.04
Security Features: Attached Options
Transaction Features: Rights Offering Annuncio • Aug 15
Genetic Technologies Limited Announces Global Launch of GeneType on Wholly Owned EasyDNA Platform Genetic Technologies Limited announced the global launch of the geneType Risk Assessment portfolio on wholly owned EasyDNA platform currently selling in 42 countries, setting the stage for the potential significant expansion of the Company's current AUD 7.5 million annual revenues. This expansion allows the Company to promote and sell its most powerful geneType innovation on its most profitable channel to realise more than 70% gross margin. This key step change in conjunction with the Company's structural reset will reduce cash burn to under AUD 200,000 per month from the previous AUD 800,000, driving the Company towards its profitability target. The availability of geneType™ on EasyDNA’s consumer platform will accelerate global access. In the US, building on the successful influencer campaigns and Stayhealthy® initiatives, the Company believes this is the right time to add geneType™ to the EasyDNA marketplace. The Company has built a streamlined online process for both clinicians and consumers with its partners, Nest Genomics, DNA Nexus, DNA Visit, Gene By Gene and Fabric Genomics. Aligned in GENE’s mission to transform the approach to population healthcare on a personalised basis, these partnerships support a telehealth-enabled access to clinical testing. The placement of the geneType™ consumer-initiated pipeline on the EasyDNA platform will increase the visibility and reach of the product line, while maintaining the required clinical oversight. This pipeline enables a uniform operational workflow regardless of specimen origin. All laboratory processing of samples will be carried out through GENE’s laboratory partner Gene By Gene. Data analysis, a critical element of GENE’s intellectual property and accreditation status, will remain in Australian-based laboratory utilizing the Company’s cloud-based algorithms allowing GENE to process data in local environments according to local data regulations by country. The new initiative, launched in July, is designed to streamline completion of the clinical questionnaire and the communication of results. GENE has implemented a “user-friendly” consumer interface with Nest Genomics. Nest Genomics are experts in the field of genetic-based, patient-facing communication enabling GENE to harness their ability to support the post-test continuum of care. GENE has not only built a test that empowers consumers to understand their risk of serious disease but has built a pipeline that enables consumers to act on that disease risk by facilitating communication with their healthcare providers. This pipeline will now be made available on the EasyDNA platform for increased consumer and practitioner access. The UK market has demonstrated a proven appetite and strong interest in genetic testing. GENE believes this initiative will resonate well in this market given much of the data that drove the initial development of geneType™ is based on the unique UK biobank. In Australia, as in the US, tests will be available via the EasyDNA platform and local medical providers using telehealth appointments and in-person engagement with consumers. The combination of genetics and clinical risk covers both nature and nurture and provides a truly comprehensive view of an individual’s personal risk of serious disease. The Company’s geneType patent portfolio, with over $50m invested to date, creates a moat in these areas as the market is expected to grow exponentially in the near term. The EasyDNA business, founded some 17 years ago, is a leading name in the consumer health and wellness markets. Its product range includes paternity testing, animal health, general consumer health and wellness across over 42 countries with the initial focus on English language markets. Annuncio • Jul 27
Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of AUD 3.997793 million. Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of AUD 3.997793 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 99,944,831
Price\Range: AUD 0.04
Transaction Features: Rights Offering Annuncio • Jun 25
Genetic Technologies Limited Share the Power of the geneType Test in Identifying Risk and Improving the Health of Populations Worldwide Genetic Technologies Limited share the power of the geneType test in identifying risk and improving the health of populations worldwide. Since the geneType Risk Assessment Tests became available, GTG has tested a statistically significant number of people in Australia and the US. These results have revealed a compelling statistic: 79.5% of individuals tested showed an elevated risk for at least one disease. GTG believes this is a significant finding driving increased surveillance and screening which will ultimately lead to early detection, early intervention and, ultimately, save lives. GeneType is revolutionizing healthcare with its pioneering, non-invasive Multi-Risk Test, designed to uncover hidden risks of common yet serious diseases. This test identifies individuals at elevated risk for a range of cancers, including breast, ovarian, pancreatic, prostate, colorectal, and melanoma, as well as cardiovascular diseases and metabolic conditions like Type 2 diabetes. Annuncio • Apr 24
Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $2 million. Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $2 million.
Security Name: American Depositary Shares
Security Type: Depositary Receipt (Common Stock)
Securities Offered: 1,000,000
Price\Range: $2
Transaction Features: Registered Direct Offering Annuncio • Apr 20
Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $11.2056 million. Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $11.2056 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 16,800,000
Price\Range: $0.667
Transaction Features: Subsequent Direct Listing Annuncio • Apr 19
Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $2 million. Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $2 million.
Security Name: American Depositary Shares
Security Type: Depositary Receipt (Common Stock)
Securities Offered: 1,000,000
Price\Range: $2
Transaction Features: Registered Direct Offering Annuncio • Apr 12
Genetic Technologies Limited Establishes Clinical Implementation Study with Breast Screen Centres Across New York, Miami and Houston Genetic Technologies Limited announced the company is establishing a clinical implementation study with breast imaging centres across New York, Miami and Houston. The initiative will pilot the integration of the geneType into breast imaging centres, assisting in the streamlining of care that is currently somewhat fragmented. It will be a significant step forward in personalised medicine, particularly in the context of breast density notification and supplemental screening options for those women at increased risk. This pioneering study stems from feedback from prominent employer and payor groups in the United States, that recognise women's healthcare, particularly around breast cancer, contains the most promising health and economic benefits. Two leading clinicians involved in the study are Sheldon M. Feldman, MD, FACS, Director of breast cancer services at Montefiore Medical Center and Elizabeth Etkin-Kramer, M.D., FACOG, OB-GYN and assistant professor at Florida International University, founder of Yodeah.org and affiliated with Mount Sinai Medical Center in Miami. Study benefits: · Risk-stratified Decision-Making: By integrating the geneType Breast Cancer Risk Assessment Test into breast imaging centers, patients at higher risk of breast cancer can be easily identified during imaging appointments. They can then be automatically triaged back into the supplementary screening process within the center. This approach empowers patients to make better decisions about their screening options while ensuring a seamless transition within the center's workflow. Additionally, to improve communication between patients' primary care providers and imaging facilities, the pilot program incorporates continuum of care software from geneType's partner, Nest Genomics, facilitating smoother communication among healthcare providers. · Enhanced Breast Density Notification and Interpretation: Breast density is a crucial risk factor that can both mask early cancer detection but is also associated with increased risk of developing cancer. Integrating the geneType test into breast imaging practices offers a more holistic approach to identifying women at increased risk of developing breast cancer by incorporating their breast density status. Risk assessment for women at the point of imaging ensures that all women receive appropriate follow-up and surveillance beyond standard screening intervals in accordance with their risk. · Increased Imaging Compliance: One of the primary outcomes of this study is to evaluate the impact of geneType on imaging compliance among at-risk populations. By exposing individualised breast cancer risks through the geneType Risk Assessment Test, patients are more likely to adhere to recommended screening protocols. The provision of personalised risk assessments should provide increased awareness among patients, motivating them to prioritise their breast health and adhere to scheduled appointments. · Implementation of GeneType: Collaborating with leading breast imaging centers will provide an excellent opportunity for integrating geneType in a high throughput clinical scenario. By fitting into these imaging center workflows, this study aims to validate the efficacy of geneType in identifying women at elevated risk of breast cancer and driving subsequent clinical imaging opportunities. This data will be important in driving broader adoption of risk assessments tests such as geneType to modify breast cancer screening and risk-reduction strategies. · Scalability and Expansion: Currently in the U.S., screening is between the ages of 40 and 74, therefore the current addressable market for geneType in this scenario is 68 million women. Recruiting these leading breast imaging centers as partners in the study provides a significant opportunity to showcase feasibility and efficacy of risk assessment application to the general population. This step serves as a template for GTG to achieve broader adoption and integration of geneType risk assessment into breast imaging practices. This not only extends the reach of personalised breast cancer risk assessment but supports the issue of breast density notification while ensuring that at-risk patients don’t fall under the radar. Breast cancer risk assessment is crucial for ensuring quality care at breast centers of excellence. GeneType is revolutionising risk assessment beyond the current gold standard of care. Its integration into breast imaging centers marks a significant shift in how breast cancer risk is evaluated. By utilising risk assessment, institutions can tailor surveillance strategies, guide women into appropriate high-risk programs, increase patient awareness of their risk, promote shared decision-making, refine clinical actions regarding breast density notification, improve patient adherence, and pave the way for broader impact across populations. Ultimately, this study heralds a new era of precision medicine in the fight against breast cancer, providing screening and risk-reduction opportunities by identifying more at-risk individuals. Annuncio • Mar 26
Genetic Technologies Limited to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare Genetic Technologies Limited announce the development of the Company’s most advanced risk assessment test for serious diseases, building on the success of the Comprehensive Hereditary Breast and Ovarian Cancer (HBOC) test. GeneType's latest innovation will be a world first; including over 200 high penetrant genes to unlock the hereditary disease risk to its current multi-test associated with the most common cancers, cardiovascular disease, and type 2 diabetes. This ground-breaking innovation enables doctors to identify nearly 100% of people at risk of disease going beyond family history, which is only responsible for 5-15%. Importantly the test includes sporadic non-hereditary disease which is linked to the remaining 85% of people. This population wide test will identify patients at risk of serious disease in nearly 70% of annual mortalities and morbidities and remains a simple non-invasive sample. GeneType is committed to clinically validated innovation advancing its current portfolio offering unparalleled insight into an individual's risk of serious diseases. This cutting-edge test represents a significant leap forward in personalized preventative healthcare, providing physicians and their patients with an unprecedented tool to tailor interventions and treatment plans. Key features of GeneType's Comprehensive Risk Assessment Test: Includes more than 200 High Penetrant Genes: GeneType's test goes beyond conventional assessments, incorporating an extensive panel of hereditary genes, ensuring a comprehensive evaluation of the individual's genetic predisposition to serious diseases whether user have a family history or not. Numerous publications have highlighted the importance of using multigene panels compared with just genetic tests for one or two genes. In one study of 10,000 patients, approximately 50% the pathogenic genes identified in patients with breast or ovarian cancer were in genes other than BRCA1/21. In the event no genetic mutations are identified, in the case of breast cancer this will be approximately 90% of patients2, the geneType Comprehensive Risk Assessment Test includes an automatic reflex that captures the majority of patients at risk of these serious diseases. Saliva Test: geneType’s patented non-invasive saliva test remains at the core of GeneType's approach, ensuring accessibility and ease for patients while maintaining the highest standards of accuracy. Oncology, Cardiovascular, and Metabolic Disease Coverage: GeneType's Comprehensive Risk Assessment Test covers a diverse range of diseases, providing physicians and patients with a complete understanding of an individual's risk profile. Annuncio • Jan 06
Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement Genetic Technologies Limited advised that it has received formal notice from the Nasdaq Stock Market, LLC (‘Nasdaq’) stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). As previously disclosed, the Company received a written notice from Nasdaq on July 17, 2023, notifying the Company that it had failed to meet the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market. To regain compliance with the Listing Rule, the Company’s American Depositary Shares (ADS) were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on December 28, 2023. Nasdaq has stated that this matter is now closed. Annuncio • Sep 30
Genetic Technologies Limited, Annual General Meeting, Nov 22, 2023 Genetic Technologies Limited, Annual General Meeting, Nov 22, 2023. Annuncio • Sep 12
Genetic Technologies Limited Announces the Expanded GeneType Multi-Risk Test Is Now Available to Order in Australia Genetic Technologies Limited announced that the expanded geneType Multi-Risk Test is now available to order in Australia. GTG announced the launch of the expanded test in the U.S., to include three new diseases, in March 2023. The three new diseases, Pancreatic Cancer, Melanoma, and Atrial Fibrillation, were approved for sale in Australia by the National Association of Testing Authority (NATA). The geneType Multi-Risk test now performs a total of nine individual serious disease risk assessments, all from the one simple saliva sample. The risk assessment panel focuses on Oncology, Cardiovascular and Metabolic diseases: Breast Cancer; Ovarian Cancer; Pancreatic Cancer Prostate Cancer; Melanoma; Colorectal Cancer; Diabetes; Coronary Artery Disease; and Atrial Fibrillation. The granting of this approval by NATA follows the approval in March this year by Centers for Medicare & Medicaid (CMS) to sell the expanded panel in the USA. The expanded Multi-test panel caters for most ethnicities over the age of 30. Each of the new diseases recently approved cause significant mortality and morbidity. According to the Australian Institute of Health and Welfare, in 2023 there will be approximately 10,639 new cases of melanoma, Australia’s third most diagnosed cancer. The estimates for pancreatic cancer are even more dire, in Australia in, 2023 it is estimated that 2,355 people will be diagnosed with pancreatic cancer and a staggering 87% of these people will die. In both cases, identifying people at increased risk provides an opportunity for early diagnosis and early intervention, leading to a significant improvement in patient outcomes, extending life expectancy, and saving lives. In the case of atrial fibrillation (AFib), surveys and studies on sections of the Australian population suggest that AFib affects approximately 2% of the general population, equivalent to more than 500,000 people. Annuncio • Feb 10
Genetic Technologies Limited Announces Publication Highlights Genetype’S Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification Genetic Technologies Limited announce the publication of a new research paper in the peer-reviewed journal Breast Cancer Research and Treatment. The paper reports results from an extensive study undertaken by the GTG Scientific Team in collaboration with eminent researchers from Harvard Medical School (United States) and the University of Melbourne (Australia). The study compared geneType’s simple breast cancer risk assessment against a complex model with more risk factors and two commonly used clinical models (Gail and IBIS). GeneType outperformed both the Gail and IBIS models by a significant margin and had equivalent performance to the Rosner model without the need to collect a substantially larger number of risk factors. The paper used data from the Nurses’ Health Study, which included 121,700 female registered nurses aged 30–55 years. In addition, the paper noted a significant improvement in performance when compared with commonly used clinical risk models for breast cancer (Gail and IBIS models). The study also showed that geneType’s simple risk prediction model showed similar performance to a robust, but more complex model (Rosner). This underscores the success of geneType’s fundamental product development objective - to create a model that performs well, but takes less time to implement in the clinic. The geneType model includes the most important risk factors for breast cancer prediction - polygenic risk score, mammographic density and family history. This study highlights GTG’s epidemiological and biostatistical expertise and application of best-practices3 for integrating polygenic risk into clinical risk prediction. In general practice, and mammography clinic settings, patient contact time can be lengthy. The simplicity of geneType, from a sample and data collection perspective using a saliva sample and brief questionnaire, facilitates a greater adoption by both patients and health care professionals, leading to the identification of a greater number of at-risk women. The paper also commented on the importance of risk-reducing medications in reducing breast cancer incidence. Despite several risk-reducing medications having been shown to reduce the risk of breast cancer, they are rarely used.4 Through the use of geneType for Breast Cancer, women who would benefit most from risk-reducing medication can be identified and a significant reduction in breast cancer incidence could be achieved. Annuncio • Feb 07
Genetic Technologies Limited Provides Further Update on Comprehensive Risk Test for Breast & Ovarian Cancer Genetic Technologies Limited provided further information at the request of the ASX in regards to the announcement released 3 February 2023. The development of this test is in direct response and feedback from the payer conversations such as insurance providers, employers, and healthcare providers. There is an unmet need to develop a unique single saliva risk assessment test that combines gene mutation for breast and ovarian cancers, hereditary and sporadic indicators and other relevant clinical risk factors. There is no other single test on the market that provides this array of information from a single test. The company has multiple patents granted and pending that support the combination of genetic and clinical risk factors. The combination of general population ovarian risk assessment and breast cancer risk assessment in a single risk test that both incorporate disease-specific polygenic risk components for low penetrant risk alleles and clinical risk factors are the novel combination. It is very common to have the two diseases paired in the high penetrant breast and ovarian susceptibility genetic testing environment as some of the genes, like BRCA1 and BRCA2 confer risk for both cancer types. But the fact is that the majority of women tested for these high penetrant breast and ovarian susceptibility genes come back with negative results, meaning they do not carry a mutation (aka pathogenic variant). Even more so, the general population prevalence, or the chance of a woman carrying a cancer susceptibility mutation for breast or ovarian cancer, is extremely low (less than 0.5% of women1). But far more women end up developing cancer (12% of women develop breast and 1.3% develop ovarian cancer in their lifetime). We know cancer isn’t just caused by “faulty genetics.” This comprehensive breast and ovarian cancer risk assessment marries a standard HBOC genetic test with the geneType risk score for both diseases. The former will benefit ~0.5% of users who get a positive result, and the remaining 99.5% of women who obtain a negative result will now have more insight to their absolute risk of developing each cancer. And if that absolute risk score comes back high, the patient and her doctor will be able to engage in shared decision-making discussions around supplemental screening and risk-reduction options that are available to at-risk women. This test would be utilized as a screening tool to risk stratify the entire general population to identify a subset of women that would not have otherwise been identified. This could lead to the individual and the physician to provide supplemental screening to achieve early detection of the diseases. The test will be commercialised through the following channels: Company’s Consumer Initiated Testing Web Platform; Business to Business relationships including, but not limited to: Insurance providers. Employers; Healthcare providers; Biotech companies developing technology in breast cancer. Direct sales to Health Care Professionals with our business development team. Annuncio • Feb 04
Genetic Technologies Limited to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer Genetic Technologies Limited announced the company will launch a ‘World First’ Comprehensive Risk Assessment Test which evaluates a women’s risk of developing Breast and/or Ovarian Cancer either from a hereditary genetic mutation or from the far more common familial or sporadic cancer. Combined with other clinical risk factors the test provides a comprehensive risk assessment in a simple saliva test. Highlights: New test integrates the patented and proprietary GeneType platform for both Breast and Ovarian Cancer. GTG’s unique approach “appends” the detection of the 13 major “actionable” breast and ovarian cancer susceptibility genes to the GeneType test platform. Results in a higher classification rate of women at elevated risk of breast and ovarian cancer than traditional clinical tools by assessing breast and ovarian cancer susceptibility from both rare and common genetic variants in addition to other known clinical risk factors associated with the development of both diseases. Advances the goal of providing population-based genetic screening for Breast and Ovarian cancer where up to 85% of cancers diagnosed do not have hereditary or family history. The new test platform addresses those women over 30 years of age in the general population that are at higher risk of developing breast and/or ovarian cancer, not just from rare genetic mutations. The comprehensive risk assessment test will be clinically validated and have appropriate regulatory approval. This test will be launched via its Business to Business (‘B2B’) and Consumer Initiated Testing (‘CIT’) channels in the United States. The Comprehensive Risk Test will be showcased at the BRCA 2023 Symposium in Montreal in early May. GTG’s comprehensive risk assessment for both cancers inform women of their risk profile and as a result, the opportunity to take proactive actions to increase screening and lessen their risk of developing these diseases. The risk assessment is performed from a single saliva sample and a brief questionnaire. Implementation of the test as a population-based genetic screening for Breast and Ovarian is supported by GTG’s independently developed Budget Impact Model (‘BIM’) providing a strong health and economic case for payers and insurers in the U.S. Supplemental screening in a subpopulation of women identified as at-risk by geneType can lead to an increase in early-stage, screen-detected cancers, which in turn is associated with high 5-year survival rates 99% and 93% for breast and ovarian, respectively.